Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

P Dombernowsky, I E Smith, Geoffrey Falkson et al. · Journal of Clinical Oncology · 1998 · 640 citations

Medicine, Oncology, Pharmacology +16

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A. U. Buzdar, W. Jonat, Anthony Howell et al. · Journal of Clinical Oncology · 1996 · 410 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

Jürgen Geisler, Nicholas King, Mitch Dowsett et al. · British Journal of Cancer · 1996 · 341 citations · Full text

Pharmacy, Endocrinology, Pharmacology +17

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *

W. Jonat, Anthony Howell, Carl Blomqvist et al. · European Journal of Cancer · 1996 · 255 citations

Medicine, Oncology, Pharmacology +14

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Mitch Dowsett, Alison Jones, Stephen Johnston et al. · PubMed · 1995 · 239 citations

Pharmacy, Pharmacology, Pharmacotherapy +17